Inflammatory cytokine signaling and mast cell degranulation

Inflammatory cytokine signaling and mast cell degranulation represent a complex biological pathway central to the immune system's response to allergens and pathogens. Mast cells are activated primarily through the cross-linking of the high-affinity IgE receptor (FceRI), leading to the rapid release of preformed mediators such as histamine and tryptase (Source: Wernersson & Pejler, Nature Reviews Immunology, 2014). This initial degranulation is followed by the synthesis of various pro-inflammatory cytokines, including TNF-alpha, IL-4, and IL-13, which orchestrate chronic inflammatory responses (Source: Galli et al., Nature, 2008). While these processes are vital for defense against parasites, their dysregulation is a hallmark of allergic asthma, atopic dermatitis, and mast cell activation syndromes (Source: Theoharides et al., NEJM, 2015). Therapeutic strategies targeting this pathway include the use of monoclonal antibodies like Omalizumab to sequester IgE and kinase inhibitors like Imatinib to block KIT signaling (Source: Stone et al., JAMA, 2010). Because this entry describes a broad physiological process involving multiple distinct proteins rather than a single molecular entity, it is classified as a pathway rather than a discrete therapeutic target.

Other names

Mast cell activation pathwayType I hypersensitivity signalingFceRI-mediated inflammatory response

Drugs modulate this pathway by inhibiting IgE binding to FceRI, stabilizing mast cell membranes to prevent mediator release, or blocking downstream cytokine receptors (e.g., IL-4R, IL-6R) and intracellular kinases like SYK and KIT (Source: StatPearls, Mast Cell Activation Syndrome; Nature Reviews Immunology, 2014).